# DEPARTMENT OF PHARMACY GURU GHASIDAS VISHWAVIDYALAYA (A CENTRAL UNIVERSITY), BILASPUR (C.G.)

# M. PHARM. (PHARMACOLOGY)

(W.E.F. SESSION 2020-21)

Course of study for M. Pharm. (Pharmacology)

Course	Course	Credit	Credit	Hrs./w k	Marks
Code		Hours	Points		
		Semester	·I		
MPL 101T	Modern	4	4	4	100
	Pharmaceutical				
	Analytical Techniques				
MPL 102T	Advanced	4	4	4	100
	Pharmacology-I				
MPL 103T	Pharmacological and	4	4	4	100
	Toxicological				
	Screening Methods-I				
MPL 104T	Cellular and	4	4	4	100
	Molecular				
	Pharmacology				
MPL 105P	Pharmacology	12	6	12	150
	Practical I				
MPL 106P	Seminar/Assignment	7	4	7	100
	Total	35	26	35	650
		Semester	II		
MPL 201T	Advanced	4	4	4	100
	Pharmacology II				
MPL 202T	Pharmacological and	4	4	4	100
	Toxicological				
	Screening Methods-II				
MPL 203T	Principles of Drug	4	4	4	100
	Discovery				
MPL 204T	Clinical Research and	4	4	4	100
	Pharmacovigilance				
MPL 205P	Pharmacology	12	6	12	150
	Practical II				
MPL 206P	Seminar/Assignment	7	4	7	100
	Total	35	26	35	650

# Schemes for internal assessments and end semester examinations (Pharmacology-MPL)

Course Code	Course	_ `	ternal A	ssessment			Semester xams	Total Marks
		Continu	Session	nal Exams	Total	Marks	Duration	1
		ous Mode	Marks	Duration				
		S	emester	I				
MPL 101T	Modern Pharmaceutical Analytical Techniques	10	15	1 Hr	25	75	3 Hrs	100
MPL 102T	Advanced Pharmacology-I	10	15	1 Hr	25	75	3 Hrs	100
MPL 103T	Pharmacological and Toxicological Screening Methods-I	10	15	1 Hr	25	75	3 Hrs	100
MPL 104T	Cellular and Molecular Pharmacology	10	15	1 Hr	25	75	3 Hrs	100
MPL 105P	Pharmacology Practical I	20	30	6 Hrs	50	100	6 Hrs	150
MPL 106P	Seminar/Assignment	-	-	-	-	-	-	100
		l	1	1		ı	Total	650
		Se	emester l	ſΤ				
MPL 201T	Advanced Pharmacology II	10	15	1 Hr	25	75	3 Hrs	100
MPL 202T	Pharmacological and Toxicological Screening Methods-II	10	15	1 Hr	25	75	3 Hrs	100
MPL 203T	Principles of Drug Discovery	10	15	1 Hr	25	75	3 Hrs	100
MPL 204T	Clinical Research and Pharmacovigilance	10	15	1 Hr	25	75	3 Hrs	100
MPL 205P	Pharmacology Practical II	20	30	6 Hrs	50	100	6 Hrs	150
MPL 206P	Seminar/Assignment	-	-	-	-	-	-	100
	·						Total	650

Course of study for M. Pharm. III Semester (Common for All Specializations)

Course Code	Course	Credit Hours	Credit Points
MRM 301T	Research	4	4
	Methodology and		
	Biostatistics*		
MRM 302P	Journal club	1	1
MRM 303P	Discussion /	2	2
	Presentation (Proposal		
	Presentation)		
MRM 304P	Research Work	28	14
	Total	35	21

<sup>\*</sup>Non University Examination

# Course of study for M. Pharm. IV Semester (Common for All Specializations)

Course Code	Course	Credit Hours	Credit Points
MRM 401P	Journal club	1	1
MRM 402P	Discussion / Final Presentation	3	3
MRM 403P	Research Work	31	16
	Total	35	20

# **Semester wise credits distribution**

Semester	Credit Points
I	26
II	26
III	21
IV	20
Co-curricular Activities (Attending	Minimum=02
Conference, Scientific Presentations and	Maximum=07*
Other Scholarly Activities)	
Total Credit Points	Minimum=95
	Maximum=100*

<sup>\*</sup>Credit Points for Co-curricular Activities

Schemes for internal assessments and end semester examinations (Semester III & IV)

Course Code	Course	In	ternal A	ssessment			Semester kams	Total Marks
Couc		Continu	Session	nal Exams	Total	Marks	Duration	1,1411
		ous	Marks	Duration	1000	111111111111111111111111111111111111111		
		Mode	IVICIIIS	Duration				
L			ı	I			I	
		Se	mester I	II				
MRM301T	Research	10	15	1 Hr	25	75	3 Hrs	100
	Methodology and							
	Biostatistics*							
MRM 302P	Journal club	-	-	-	25	-	-	25
MRM 303P	Discussion /	-	-	-	50	-	-	50
	Presentation							
	(Proposal							
	Presentation)							
MRM 304P	Research work*	-	-	-	-	350	1 hr	350
			•			'	Total	525
								1
		Se	mester I	$\mathbf{V}$				
MRM401P	Journal club	-	-	-	25	-	-	25
MRM402P	Discussion /	-	-	-	75	-	-	75
	Presentation							
	(Proposal							
	Presentation)							
MRM403P	Research work and	-	-	-	-	400	1 hr	400
	Colloquium							
			1		1	1	Total	500

<sup>\*</sup>Non University Examination

# M. Pharm. (Pharmacology)

#### **Programme Outcomes**

#### Postgraduate's students will be able to

**PO1:** Fundamentals on advanced analytical instrumental techniques: UV-Visible, IR, Spectroflourimetry, Flame emission and Atomic absorption spectroscopy, NMR spectroscopy, Mass Spectroscopy, Chromatography, Electrophoresis and Immunological assays methods.

PO2: Advanced knowledge in field of pharmacology: Pharmacokinetics, Pharmacodynamics, Neurotransmission, Systemic Pharmacology, pathophysiology of diseases, Parasympathomimetics and lytics, sympathomimetics and lytics, Central nervous system, cardiovascular and autocoids Pharmacology.

PO3: knowledge on preclinical evaluation of drugs and recent experimental techniques in the drug discovery: Common laboratory animals, Anaesthesia and euthanasia of experimental animals, Bioassay, Preclinical screening of new substances for the pharmacological activity, Preclinical screening of new substances, immunoassay.

**PO4:** Fundamental knowledge on the structure and functions of cellular components: Cell biology, cell cycle and its regulation, Cell death, Cell signaling, genomic and proteomic tools, intracellular signaling pathways, Recombinant DNA technology and gene therapy, Pharmacogenomics.

PO5: Knowledge of recent advances in the drugs used for the treatment of various diseases: Endocrine Pharmacology, Chemotherapy, Immunopharmacology, GIT Pharmacology, Chronopharmacology, Free radicals Pharmacology.

PO6: Imparts knowledge on the preclinical safety and toxicological evaluation of drug: OECD, ICH, EPA and Schedule Y, Reproductive toxicology studies, Genotoxicity studies, In vivo carcinogenicity studies, Toxicokinetics.

PO7: Knowledge of drug discovery, clinical research and pharmacovigilance: lead identification and lead Optimization, Economics of drug discovery, Rational Drug Design, Molecular docking, 3D-QSAR approaches like COMFA and COMSIA, Good Clinical Practice (ICH-GCP) guidelines, Pharmacoepidemiology, pharmacoeconomics.

PO8: Knowledge about Research Methodology & Biostatistics: review of literature, strategies to eliminate errors/bias, values in medical ethics, CPCSEA guidelines for laboratory animal facility, Declaration of Helsinki.

# **First Semester**

# MODERN PHARMACEUTICAL ANALYTICAL TECHENIQUES (MPL101T)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL101T	3	1	-	4 hours	25	75	100	4

# Scope

This subject deals with various advanced analyticalinstrumental techniques for identification, characterization and quantification of drugs. Instruments dealt are NMR, Mass spectrometer, IR, HPLC, GC etc.

#### **Objectives**

After completion of course student is able to know,

- Chemicals and Excipients
- The analysis of various drugs in single and combination dosage forms
- Theoretical and practical skills of the instruments

# Theory (60 Hrs)

- 1. a. UV-Visible spectroscopy: Introduction, Theory, Laws, 10 with Instrumentation associated **UV-Visible** spectroscopy. Hrs Choice of solvents and solvent effect and Applications of UV-Visible spectroscopy.
  - b. IR spectroscopy: Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy.
  - c. Spectroflourimetry: Theory of Fluorescence, Factors affecting fluorescence, Quenchers, Instrumentation and Applications of fluorescence spectrophotometer.
  - d. Flame emission spectroscopy and Atomic absorption spectroscopy: Principle, Instrumentation Interference and Applications.

e.

- 2 NMR spectroscopy: Quantum numbers and role in NMR, Principle, 10 their Instrumentation. Solvent requirement in NMR. Relaxation process, NMR signals in various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic Brief outline of principles of FT-NMR and 13C double resonance, of NMR spectroscopy. NMR. Applications
- 3. Mass Spectroscopy: Principle, Theory, Instrumentation of Mass Spectroscopy, 10
  Different types of ionization like electron impact, chemical, field, FAB Hrs and MALDI, APCI, ESI, APPI Analyzers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy
- 4 Chromatography: Principle, apparatus, instrumentation, 10 chromatographic parameters, factors affecting resolution, isolation Hrs of drug from excipients, data interpretation and applications of the

#### following:

- j) Thin Layer chromatography
- k) High Performance Thin Layer Chromatography
- 1) Ion exchange chromatography
- m) Column chromatography
- n) Gas chromatography
- o) High Performance Liquid chromatography
- p) Ultra High Performance Liquid chromatography
- q) Affinity chromatography
- r) Gel Chromatography
- 5 Electrophoresis: Principle, Instrumentation, Working conditions, factors 10 affecting separation and applications of the following:
  - a) Paper electrophoresis b) Gel electrophoresis c) Capillary electrophoresis
  - d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing
  - X ray Crystallography: Production of X rays, Different X ray diffraction methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.
- 6 Potentiometry: Principle, working, Ion selective Electrodes and 10Hr Application of potentiometry. S Thermal Techniques: Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, calibration, heating and cooling rates, resolution, source of errors) and their influence. advantage and disadvantages, pharmaceutical applications. Differential Thermal Analysis (DTA): Principle, instrumentation and advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage disadvantages, pharmaceutical applications. and

#### **REFERENCES**

- 1. Spectrometric Identification of Organic compounds Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.
- 2. Principles of Instrumental Analysis Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern press, Bangalore, 1998.
- 3. Instrumental methods of analysis Willards, 7th edition, CBS publishers.
- 4. Practical Pharmaceutical Chemistry Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.
- 5. Organic Spectroscopy William Kemp, 3rd edition, ELBS, 1991.
- 6. Quantitative Analysis of Drugs in Pharmaceutical formulation P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.
- 7. Pharmaceutical Analysis- Modern methods Part B J W Munson, Vol 11, Marcel Dekker Series
- 8. Spectroscopy of Organic Compounds, 2 ndedn., P.S/Kalsi, Wiley estern Ltd., Delhi.
- 9. Textbook of Pharmaceutical Analysis, KA.Connors, 3 rd Edition, John Wiley & Sons, 1982.

#### Course Outcomes

After completion of course student is able to know

CO1. The identification, characterization, and quantification of drugs using a variety of sophisticated analytical instrumental techniques including instruments such as mass spectrometers, IR, HPLC, GC, etc.

**CO2.** The analysis of various drugs in single and combination dosage forms.

**CO3.** Theoretical and practical skills of the instruments.

Course Outcomes and their mapping with Programme Outcomes:

CO		PO									
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8			
CO1	3	1	1	1	1	1	1	1			
CO <sub>2</sub>	3	1	2	1	1	1	1	1			
CO <sub>3</sub>	3	1	1	1	1	1	1	1			

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

### ADVANCED PHARMACOLOGY - I (MPL 102T)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 102T	4	-	-	4 hours	25	75	100	4

#### Scope

The subject is designed to strengthen the basic knowledge in the field of pharmacology and to impart recent advances in the drugs used for the treatment of various diseases. In addition, this subject helps the students to understand the concepts of drug action and mechanisms involved

#### **Objectives**

Upon completion of the course, student shall be able to:

- Discuss the pathophysiology and pharmacotherapy of certain diseases
- Explain the mechanism of drug actions at cellular and molecular level
- Understand the adverse effects, contraindications and clinical uses of drugs used in treatment of diseases

#### Theory (60 Hrs)

1. General Pharmacology

12 Pharmacokinetics: The absorption, Hrs dynamics of drug distribution, biotransformation and elimination. Concepts of linear and non-

linear compartment models. Significance of Protein

binding.

- Pharmacodynamics: b. Mechanism of drug action and the between relationship drug concentration and effect. Receptors, structural functional and families of receptors, quantitation of drug receptors interaction and elicited
- 2 Neurotransmission

12

a. General aspects and steps involved in neurotransmission.

- b. Neurohumoral transmission in autonomic nervous system (Detailed study about neurotransmitters-Adrenaline and Acetyl choline). (Detailed Neurohumoral transmission in central system nervous neurotransmittersdopamine, study about histamine, serotonin, GABA, glutamate and glycine]. adrenergic cholinergic (NANC). d. Non transmission Conon transmission Systemic Pharmacology A detailed study on pathophysiology of diseases, mechanism of pharmacology and toxicology existing well novel action, as as drugs used in the following systems Autonomic Pharmacology Parasympathomimetics sympathomimetics lytics, and lytics, and agents affecting neuromuscular junction 3 Central nervous system Pharmacology 12 General and local anesthetics Hrs Sedatives and hypnotics, drugs used to treat anxiety. Depression, psychosis, mania, epilepsy, neurodegenerative diseases. Narcotic and non-narcotic analgesics. 4 Cardiovascular Pharmacology 12 antihypertensives, Diuretics. antiischemics. antiarrhythmics, Hrs drugs for heart failure and hyperlipidemia. Hematinics, coagulants, anticoagulants, fibrinolytics and antiplatelet 5 Autocoid Pharmacology 12 The physiological and pathological role of Histamine, Serotonin, Hrs Kinins Prostaglandins Opioid autocoids. Pharmacology of antihistamines, 5HT antagonists. **REFERENCES** 1. The Pharmacological Basis of Therapeutics, Goodman and Gillman's 2. Principles of Pharmacology. The Pathophysiologic basis of drug Therapy
  - by David E Golan, Armen H, TashjianJr, EhrinJ, Armstrong, April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers.
  - 3. Basic and Clinical Pharmacology by B.G Katzung
  - 4. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.
  - 5. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel Andrew B.C.Yu.
  - 6. Graham Smith. Oxford textbook of Clinical Pharmacology.
  - 7. Avery Drug Treatment
  - 8. Dipiro Pharmacology, Pathophysiological approach.
  - 9. Green Pathophysiology for Pharmacists
  - 10. Robbins &Cortan Pathologic Basis of Disease, th Ed. (Robbins Pathology)
  - 11. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company
  - 12. KD. Tripathi. Essentials of Medical Pharmacology.

- 13. Modern Pharmacology with Clinical Applications, Craig Charles R. & Stitzel Robert E., Lippincott Publishers.
- 14. Clinical Pharmacokinetics & Pharmacodynamics: Concepts and Applications Malcolm Rowland and Thomas N.Tozer, Wolters Kluwer, Lippincott Williams & Wilkins Publishers.
- 15. Applied biopharmaceutics and Pharmacokinetics, Pharmacodynamics and Drug metabolism for industrial scientists.
- 16. Modern Pharmacology, Craig CR. & Stitzel RE, Little Brown & Company

#### **Course Outcomes**

The student will try to learn-

CO1. Cellular and molecular basis of drug action.

**CO2.** Negative effects, contraindications, and clinical applications of medications used to treat diseases.

### **Course Outcomes and their mapping with Programme Outcomes:**

CO		PO								
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8		
<b>CO1</b>	1	1	3	3	1	2	3	1		
CO <sub>2</sub>	1	2	3	3	2	1	2	2		

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

# PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS - I (MPL 103T)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 103T	4	-	ı	4 hours	25	75	100	4

## Scope

This subject is designed to impart the knowledge on preclinical evaluation of drugs and recent experimental techniques in the drug discovery and development. The subject content helps the student to understand the maintenance of laboratory animals as per the guidelines, basic knowledge of various in-vitro and in-vivo preclinical evaluation processes

#### **Objectives**

Upon completion of the course, student shall be able to

- Appraise the regulations and ethical requirement for the usage of experimental animals.
- Describe the various animals used in the drug discovery process and good laboratory practices in maintenance and handling of experimental animals
- Describe the various newer screening methods involved in the drug discovery process
- Appreciate and correlate the preclinical data to humans

#### Theory (60 Hrs)

- 1. Laboratory Animals Common laboratory animals: Description, handling and applications of different species and strains of animals.

  Hrs
  - Transgenic animals: Production, maintenance and applications
  - Anaesthesia and euthanasia of experimental animals.
  - Maintenance and breeding of laboratory animals.
  - CPCSEA guidelines to conduct experiments on animals
  - Good laboratory practice.
  - Bioassay-Principle, scope and limitations and Methods
- 2 Preclinical screening for 12 of new substances the pharmacological activity using in vivo, in vitro, and other Hrs possible animal alternative models.
  - General principles of preclinical screening. CNS Pharmacology:
  - behavioral and muscle co-ordination, CNS stimulants and
  - depressants, anxiolytics, anti-psychotics, antiepileptics and
  - Drugs for neurodegenerative diseases like Parkinsonism,
  - Alzheimers and multiple sclerosis. Drugs acting on

    Autonomic Nervous

nootropics.

- System.
- 3 Preclinical screening of new substances for the 12 pharmacological activity in vitro, and other Hrs using vivo, in possible animal alternative models.
  - Respiratory Pharmacology: anti-asthmatics, drugs for **COPD** and anti allergics. Pharmacology: Reproductive **Aphrodisiacs** and antifertility Analgesics, agents antiinflammatory and antipyretic ulcer, agents. Gastrointestinal drugs: anti anti -emetic, antidiarrheal and laxatives.
- 4 Preclinical screening of substances for the 12 new pharmacological activity other Hrs using in vitro, and in vivo, possible animal alternative models. Cardiovascular Pharmacology: antihypertensives, antiarrythmics,
  - antianginal, antiatherosclerotic agents and diuretics. Drugs for metabolic disorders like anti-diabetic, antidyslipidemic agents. Anti cancer agents. Hepatoprotective screening methods.
- 5 Preclinical screening of new substances for the 12 pharmacological activity using in vivo, in vitro. and other Hrs possible animal alternative models.
  - Immunomodulators, Immunosuppressants and immunostimulants
  - principles General of immunoassay: theoretical basis and optimization of heterogeneous homogenous immunoassay, and immunoassay evaluation: Immunoassav methods systems. protocol outline, objectives preparation. **Immunoassay** for and digoxin and insulin
  - Limitations of animal experimentation and alternate animal experiments. Extrapolation of in vitro data to preclinical and preclinical to humans

#### REFERENCES

- 1. Biological standardization by J.H. Burn D.J. Finney and I.G. Goodwin
- 2. Screening methods in Pharmacology by Robert Turner. A
- 3. Evaluation of drugs activities by Laurence and Bachrach

- 4. Methods in Pharmacology by Arnold Schwartz.
- 5. Fundamentals of experimental Pharmacology by M.N.Ghosh
- 6. Pharmacological experiment on intact preparations by Churchill Livingstone
- 7. Drug discovery and Evaluation by Vogel H.G. 8. Experimental Pharmacology by R.K.Goyal.
- 8. Preclinical evaluation of new drugs by S.K. Guta
- 9. Handbook of Experimental Pharmacology, SK.Kulkarni
- 10. Practical Pharmacology and Clinical Pharmacy, SK.Kulkarni, 3<sup>rd</sup> Edition.
- 11. David R.Gross. Animal Models in Cardiovascular Research, 2<sup>nd</sup> Edition, Kluwer Academic Publishers, London, UK.
- 12. Screening Methods in Pharmacology, Robert A.Turner.
- 13. Rodents for Pharmacological Experiments, Dr. Tapan Kumar chatterjee.
- 14. Practical Manual of Experimental and Clinical Pharmacology by Bikash
- 15. Medhi (Author), Ajay Prakash (Author)

#### **Course Outcomes**

The student will try to learn-

- **CO1.** Laws and moral standards governing the use of experimental animals.
- CO2. Different types of animals employed in the drug development process and best techniques for maintaining and handling experimental animals in the lab.
- **CO3**. Many modern screening techniques used in the drug discovery process.

# **Course Outcomes and their mapping with Programme Outcomes:**

CO		PO									
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8			
<b>CO1</b>	1	1	3	1		3					
CO <sub>2</sub>	1	2	3	2		1					
CO3	1	3	3	3		1					

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

#### CELLULAR AND MOLECULAR PHARMACOLOGY (MPL 104T)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 104T	4	-	-	4 hours	25	75	100	4

#### Scope

The subject imparts a fundamental knowledge on the structure and functions of cellular components and help to understand the interaction of these components with drugs. This information will further help the student to apply the knowledge in drug discovery process.

#### **Objectives**

Upon completion of the course, it is expected that the students shall be able to

- Explain the receptor signal transduction processes.
- Explain the molecular pathways affected by drugs.

- Appreciate the applicability of molecular pharmacology and biomarkers in drug discovery process.
- Demonstrate molecular biology techniques as applicable for pharmacology

# Theory (60 Hrs)

1. Cell biology

12

Structure and functions of cell and its organelles

Hrs

regulation, Genome organization. Gene expression and its of siRNA importance RNA, mapping and gene and micro gene sequencing

Cell cycles and its regulation.

Cell death— events, regulators, intrinsic and extrinsic pathways of apoptosis.

Necrosis and autophagy.

2 Cell signaling

12

Intercellular and intracellular signaling pathways.

Hrs

Classification of receptor family and molecular structure ligand gated ion channels; G-protein coupled receptors, tyrosine kinase receptors and nuclear receptors.

Secondary messengers: cyclic AMP, cyclic GMP, calcium ion, inositol 1,4,5-trisphosphate, (IP3), NO, and diacylglycerol.

study following intracellular Detailed of signaling pathways: cvclic **AMP** pathway, mitogen-activated protein signaling kinase (MAPK) (JAK)/signal transducer and signaling. Janus kinase activator of transcription (STAT) signaling pathway.

3 Principles and applications genomic and proteomic tools 12 DNA electrophoresis, **PCR** (reverse transcription and real time), Hrs Gene sequencing, micro array technique, SDS page, **ELISA** and western blotting,

Recombinant DNA technology and gene therapy

Basic principles of recombinant DNA technology-Restriction enzymes, various types of vectors. Applications of recombinant DNA technology.

Gene therapy- Various types of gene transfer techniques, clinical applications and recent advances in gene therapy.

4 Pharmacogenomics

Gene mapping and cloning of disease gene.

Genetic variation and its role in health/ pharmacology

Polymorphisms affecting drug metabolism

Genetic variation in drug transporters

Genetic variation in G protein coupled receptors

Applications of proteomics science: Genomics, proteomics, metabolomics, functionomics, nutrigenomics

Immunotherapeutics

Types of immunotherapeutics, humanisation antibody therapy,

Immunotherapeutics in clinical practice

5 a. Cell culture techniques

Basic equipments used in cell culture lab. Cell culture media, various types of cell culture, general procedure for cell cultures;

isolation of cells, subculture, cryopreservation, characterization of cells and their application.

Principles and applications of cell viability assays, glucose uptake assay, Calcium influx assays

Principles and applications of flow cytometry

b. Biosimilars

#### **REFERENCES**

- 1. The Cell, A Molecular Approach. Geoffrey M Cooper.
- 2. Pharmacogenomics: The Search for Individualized Therapies. Edited by J. Licinio and M -L. Wong
- 3. Handbook of Cell Signaling (Second Edition) Edited by Ralph A. et.al
- 4. Molecular Pharmacology: From DNA to Drug Discovery. John Dickenson et.al
- 5. Basic Cell Culture protocols by CherilD.Helgason and Cindy L.Miller
- 6. Basic Cell Culture (Practical Approach ) by J. M. Davis (Editor)
- 7. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)
- 8. Current porotocols in molecular biology vol I to VI edited by Frederick M.Ausuvelet la.

#### **Course Outcomes**

The student will try to learn-

**CO1.** The steps involved in receptor signal transduction.

CO2. Molecular pharmacology and biomarkers used in the drug discovery process.

#### Course Outcomes and their mapping with Programme Outcomes:

CO		PO									
	PO1	PO1 PO2 PO3 PO4 PO5 PO6 PO7 PO8									
CO1				3	2						
CO <sub>2</sub>				3	2		1				

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

#### PHARMACOLOGICAL PRACTICAL - I (MPL 105P)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 105P	-	-	12	12 hours	50	100	150	6

- 1. Analysis of pharmacopoeial compounds and their formulations by UV Vis spectrophotometer
- 2. Simultaneous estimation of multi component containing formulations by UV spectrophotometry
- 3. Experiments based on HPLC
- 4. Experiments based on Gas Chromatography
- 5. Estimation of riboflavin/quinine sulphate by fluorimetry
- 6. Estimation of sodium/potassium by flame photometry

#### Handling of laboratory animals.

1. Various routes of drug administration.

- 2. Techniques of blood sampling, anesthesia and euthanasia of experimental animals.
- 3. Functional observation battery tests (modified Irwin test)
- 4. Evaluation of CNS stimulant, depressant, anxiogenics and anxiolytic, anticonvulsant activity.
- 5. Evaluation of analgesic, anti-inflammatory, local anesthetic, mydriatic and miotic activity.
- 6. Evaluation of diuretic activity.
- 7. Evaluation of antiulcer activity by pylorus ligation method.
- 8. Oral glucose tolerance test.
- 9. Isolation and identification of DNA from various sources (Bacteria, Cauliflower, onion, Goat liver).
- 10. Isolation of RNA from yeast
- 11. Estimation of proteins by Braford/Lowry's in biological samples.
- 12. Estimation of RNA/DNA by UV Spectroscopy
- 13. Gene amplification by PCR.
- 14. Protein quantification Western Blotting.
- 15. Enzyme based in-vitro assays (MPO, AChEs, α amylase, α glucosidase).
- 16. Cell viability assays (MTT/Trypan blue/SRB).
- 17. DNA fragmentation assay by agarose gel electrophoresis.
- 18. DNA damage study by Comet assay.
- 19. Apoptosis determination by fluorescent imaging studies.
- 20. Pharmacokinetic studies and data analysis of drugs given by different routes of administration using softwares
- 21. Enzyme inhibition and induction activity
- 22. Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (UV)
- 23. Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (HPLC)

#### REFERENCES

- 1. CPCSEA, OECD, ICH, USFDA, Schedule Y, EPA guidelines,
- 2. Fundamentals of experimental Pharmacology by M.N.Ghosh
- 3. Handbook of Experimental Pharmacology by S.K. Kulkarni.
- 4. Drug discovery and Evaluation by Vogel H.G.
- 5. Spectrometric Identification of Organic compounds Robert M Silverstein,
- 6. Principles of Instrumental Analysis Doglas A Skoog, F. James Holler, Timothy A. Nieman,
- 7. Vogel's Text book of quantitative chemical analysis Jeffery, Basset, Mendham, Denney,
- 8. Basic Cell Culture protocols by Cheril D. Helgason and Cindy L.Mille
- 9. Basic Cell Culture (Practical Approach ) by J. M. Davis (Editor)
- 10. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)
- 11. Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi(Author), Ajay Prakash (Author) Jaypee brothers' medical publishers Pvt. Ltd

#### **Course Outcomes**

The student will try to learn-

**CO1.** Analysis of Pharmacopoeial compounds and their formulations by UV-Vis spectrophotometer, RNA & DNA estimation.

CO2. Experiments based on Column chromatography, HPLC, Gas chromatography.

**CO3.** Handling of laboratory animals.

# **Course Outcomes and their mapping with Programme Outcomes:**

CO		PO									
	PO1	PO1 PO2 PO3 PO4 PO5 PO6 PO7 PO8									
CO1	3										
CO <sub>2</sub>	3										
CO3			3			3					

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

# **Second Semester**

#### **ADVANCED PHARMACOLOGY - II (MPL 201T)**

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 201T	4	-	-	4 hours	25	75	100	4

#### Scope

The subject is designed to strengthen the basic knowledge in the field of pharmacology and to impart recent advances in the drugs used for the treatment of various diseases. In addition, the subject helps the student to understand the concepts of drug action and mechanism involved

#### **Objectives**

Upon completion of the course the student shall be able to:

- Explain the mechanism of drug actions at cellular and molecular level
- Discuss the Pathophysiology and pharmacotherapy of certain diseases
- Understand the adverse effects, contraindications and clinical uses of drugs used in treatment of diseases

#### Theory (60 Hrs)

1. Endocrine Pharmacology

12

Molecular and cellular mechanism of action of hormones such as Hrs growth hormone, prolactin, thyroid, insulin and sex hormones
Anti-thyroid drugs, Oral hypoglycemic agents, Oral

contraceptives, Corticosteroids.

Drugs affecting calcium regulation

2 Chemotherapy

12

Cellular and molecular mechanism of actions and resistance of Hrs antimicrobial agents

such as ß-lactams, aminoglycosides, quinolones, Macrolide antibiotics. Antifungal, antiviral, and anti-TB drugs.

3 Chemotherapy
Drugs used in Protozoal Infections

12 Hrs

Drugs used in the treatment of Helminthiasis

Chemotherapy of cancer

Immunopharmacology

Cellular and biochemical mediators of inflammation and immune

response. Allergic or

hypersensitivity reactions. Pharmacotherapy of asthma and COPD.

Immunosuppressants and Immunostimulants

4 GIT Pharmacology

12 Hrs

Antiulcer drugs, Prokinetics, antiemetics, anti-diarrheals and drugs for constipation

and irritable bowel syndrome.

Chronopharmacology

Biological and circadian rhythms, applications of chronotherapy in various diseases like

cardiovascular disease, diabetes, asthma and peptic ulcer

5 Free radicals Pharmacology

12

Generation of free radicals, role of free radicals in etiopathology of Hrs various diseases

such as diabetes, neurodegenerative diseases and cancer.

Protective activity of certain important antioxidant

Recent Advances in Treatment:

Alzheimer's disease, Parkinson's disease, Cancer, Diabetes mellitus

## **REFERENCES**

- 1. The Pharmacological basis of therapeutics- Goodman and Gill man's
- 2. Principles of Pharmacology. The Pathophysiologic basis of drug therapy by David E Golan et al.
- 3. Basic and Clinical Pharmacology by B.G -Katzung
- 4. Pharmacology by H.P. Rang and M.M. Dale.
- 5. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.
- 6. Text book of Therapeutics, drug and disease management by E T. Herfindal and Gourley.
- 7. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
- 8. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists
- 9. Robbins &Cortan Pathologic Basis of Disease, 9 th Ed. (Robbins Pathology)
- 10. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company.
- 11. KD. Tripathi. Essentials of Medical Pharmacology
- 12. Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, TashjianJr, EhrinJ,Armstrong, April W. Armstrong, Wolter, Kluwer-Lippincott Williams & Publishers

#### **Course Outcomes**

The student will try to learn-

**CO1.** Pathophysiology and pharmacotherapy of certain diseases.

CO2. Adverse effects, contraindications and clinical uses of drugs used in treatment of diseases.

**Course Outcomes and their mapping with Programme Outcomes:** 

CO		PO									
	PO1	PO1 PO2 PO3 PO4 PO5 PO6 PO7 PO8									
CO1		3			3						
CO <sub>2</sub>		3			3						

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

# PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS-II (MPL 202T)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 202T	4	-	-	4 hours	25	75	100	4

### Scope

This subject imparts knowledge on the preclinical safety and toxicological evaluation of drug & new chemical entity. This knowledge will make the student competent in regulatory toxicological evaluation.

#### **Objectives**

Upon completion of the course, the student shall be able to,

- Explain the various types of toxicity studies.
- Appreciate the importance of ethical and regulatory requirements for toxicity studies.
- Demonstrate the practical skills required to conduct the preclinical toxicity studies.

#### Theory (60 Hrs)

60 Hrs

- 1. Basic definition and types of toxicology (general, mechanistic, 12 regulatory and descriptive)

  Hrs.
  - Regulatory guidelines for conducting toxicity studies OECD, ICH, EPA and Schedule Y
  - OECD principles of Good laboratory practice (GLP)
  - History, concept and its importance in drug development
- 2 Acute, sub-acute and chronic- oral, dermal and inhalational 12 studies as per OECD guidelines.
  - Acute eye irritation, skin sensitization, dermal irritation & dermal toxicity studies.
  - Test item characterization- importance and methods in regulatory toxicology
- 3 Reproductive toxicology studies, Male reproductive toxicity 12

studies, female reproductive studies (segment I and segment III), Hrs teratogenecity studies (segment II)

Genotoxicity studies (Ames Test, in vitro and in vivo Micronucleus and Chromosomal aberrations studies)

In vivo carcinogenicity studies

- 4 IND enabling studies (IND studies)- Definition of IND, importance of 12 IND, industry perspective, list of studies needed for IND Hrs submission.
  - Safety pharmacology studies- origin, concepts and importance of safety pharmacology.
  - Tier1- CVS, CNS and respiratory safety pharmacology, HERG assay. Tier2- GI, renal and other studies
- 5 Toxicokinetics- Toxicokinetic evaluation in preclinical studies, 12 saturation kinetics Importance and applications of toxicokinetic Hrs studies. Alternative methods to animal toxicity testing.

#### **REFERENCES**

- 1. Hand book on GLP, Quality practices for regulated non-clinical research and development (http://www.who.int/tdr/publications/documents/glp-handbook.pdf).
- 2. Schedule Y Guideline: drugs and cosmetics (second amendment) rules, 2005, ministry of health and family welfare (department of health) New Delhi
- 3. Drugs from discovery to approval by Rick NG.
- 4. Animal Models in Toxicology, 3rd Edition, Lower and Bryan
- 5. OECD test guidelines.
- 6. Principles of toxicology by Karen E. Stine, Thomas M. Brown.
- 7. Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073246.pdf)

#### **Course Outcomes**

The student will try to learn-

**CO1.** Preclinical safety and toxicity assessment of drugs and novel chemical entities.

CO2. Regulatory toxicological evaluations.

#### **Course Outcomes and their mapping with Programme Outcomes:**

CO		PO									
	PO1	O1 PO2 PO3 PO4 PO5 PO6 PO7 PO8									
CO1						3		2			
CO <sub>2</sub>						3		2			

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

#### PRINCIPLES OF DRUG DISCOVERY (MPL 203T)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 203T	4	-	-	4 hours	25	75	100	4

#### Scope

The subject imparts basic knowledge of drug discovery process. This information will make the student competent in drug discovery process

#### **Objectives**

Upon completion of this course it is expected that students will be able to

- Explain the various stages of drug discovery.
- Appreciate the importance of the role of genomics, proteomics and bioinformatics in drug discovery
- Explain various targets for drug discovery.
- Explain various lead seeking method and lead optimization
- Appreciate the importance of the role of computer aided drug design in drug discovery

# Theory (60 Hrs)

- overview of modern drug discovery 1. An process: Target 12 identification. validation. lead identification lead Hrs target and Optimization. Economics of drug discovery. Discovery validation-Role Genomics. **Proteomics** Target and of Bioinformatics. Role of and Nucleic acid microarrays, Protein microarrays, technologies, Antisense siRNAs, antisense oligonucleotides, transgenic Zinc finger proteins. Role of animals
- 2 Lead Identificationcombinatorial chemistry & high throughput 12 screening. in silico lead discovery techniques, Assay development Hrs for hit identification.

Protein structure

analysis and relationship between them.

in target validation.

Levels of protein structure, Domains, motifs, and folds in protein structure. Computational prediction of protein structure: Threading and homology modeling methods. Application of NMR and X-ray crystallography in protein structure prediction

- Rational Drug Design 12 Traditional vs rational drug design, Methods followed in traditional Hrs design, High throughput screening, Concepts of drug Rational Design Methods: Drug Design, Rational Drug Structure and Pharmacophore based approaches Virtual Screening techniques: Drug likeness
  - Virtual Screening techniques: Drug likeness screening, Concept of pharmacophore mapping and pharmacophore based Screening,
- docking: Rigid Molecular docking. flexible docking. manual 12 docking; Docking based screening. De novo drug design. Hrs Quantitative analysis of Structure Activity Relationship development of History and OSAR. SAR versus OSAR. Physicochemical parameters, Hansch analysis, Fee Wilson

**OSAR** Statistical 12 methods regression analysis, partial square analysis (PLS) and other multivariate statistical methods. 3D-QSAR Hrs approaches like COMFA and COMSIA design-Basic Prodrug concept, Prodrugs improve acceptability, Drug solubility, Drug absorption and distribution, site drug delivery and sustained drug action. Rationale of prodrug design and practical consideration of prodrug

#### REFERENCES

- Reviews 1. MouldySioud. Target Discovery and Validation and Protocols: Volume Emerging Molecular Targetsand Treatment 2007 Options. Humana Press Inc.
- 2. Darryl León. Scott MarkelIn. Silico Technologies in Drug Target Identification and Validation. 2006 by Taylor and Francis Group, LLC.
- 3. Johanna K. DiStefano. Disease Gene Identification. Methods and Protocols. Springer New York Dordrecht Heidelberg London.
- 4. Hugo Kubiny. QSAR: Hansch Analysis and Related Approaches. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH
- 5. Klaus Gubernator, Hans-Joachim Böhm. Structure-Based Ligand Design. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH
- 6. Abby L .Parrill. M Rami Reddy. Rational Drug Design. Novel Methodology Symposium and Practical Applications. **ACS** Series; American Chemical Society: Washington, DC, 1999.
- 7. J. Rick Turner. New drug development design, methodology and, analysis. John Wiley & Sons, Inc., New Jersey

#### **Course Outcomes**

The student will try to learn-

**CO1.** The basics of the drug discovery process.

**CO2.** Competency in the drug discovery process using this information.

**Course Outcomes and their mapping with Programme Outcomes:** 

CO		PO									
	PO1	PO1 PO2 PO3 PO4 PO5 PO6 PO7 PO8									
CO1				2			3				
CO <sub>2</sub>				1			3				

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

#### CLINICAL RESEARCH AND PHARMACOVIGILANCE (MPL 204T)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 204T	4	-	-	4 hours	25	75	100	4

# Scope

This subject will provide a value addition and current requirement for the students in clinical research and pharmacovigilance. It will teach the students on conceptualizing, designing, conducting, managing and reporting of clinical trials.

This subject also focuses on global scenario of Pharmacovigilance in different methods that can be used to generate safety data. It will teach the students in developing drug safety data in Pre-clinical, Clinical phases of Drug development and post market surveillance.

#### **Objectives**

Upon completion of the course, the students shall be able to,

- Explain the regulatory requirements for conducting clinical trial
- Demonstrate the types of clinical trial designs
- Explain the responsibilities of key players involved in clinical trials
- Execute safety monitoring, reporting and close-out activities
- Explain the principles of Pharmacovigilance
- Detect new adverse drug reactions and their assessment
- Perform the adverse drug reaction reporting systems and communication in Pharmacovigilance

#### Theory (60 Hrs)

- 1. Regulatory Perspectives of Clinical Trials:

  Origin and Principles of International Conference
  - Origin and Principles of International Conference on Hrs Harmonization - Good Clinical Practice (ICH-GCP) guidelines

12

- Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant-Schedule Y, ICMR
- Informed Consent Process: Structure and content ofan Ethical Informed Consent Process principles governing informed consent process
- 2 Clinical Trials: Types and Design
  Experimental Study- RCT and Non RCT,
  Hrs
  - Observation Study: Cohort, Case Control, Cross sectional
  - Clinical Trial Study Team
  - Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management
- Guidelines of12 Clinical Trial Documentationto the preparation Case Hrs documents. Preparation of protocol, Investigator Brochure. Forms, Clinical Study Report Clinical Trial Monitoring Report Safety Monitoring in CT
  - Adverse Drug Reactions: Definition and types. Detection reporting methods. Severity and seriousness preventability assessment.Predictability and assessment, Management of adverse drug reactions; Terminologies of ADR.
- 4 Basic aspects, terminologies and establishment of 12 pharmacovigilance

  Hrs

History and progress of pharmacovigilance, Significance safety Pharmacovigilance India monitoring. in and international aspects, WHO international drug monitoring programme, WHO and terminologies of ADR, Regulatory evaluation of medication safety, Establishing pharmacovigilance centres in Hospitals. Industry and programmes National related to pharmacovigilance. Roles and responsibilities in Pharmacovigilance

- Methods. in 12 ADR reporting and tools used Pharmacovigilance Hrs International classification of diseases. International Nonproprietary Passive Active names for drugs, and surveillance. Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system authorities, Guidelines **ADRs** and Reporting to regulatory for reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.
- 6 Pharmacoepidemiology, pharmacoeconomics, safety 12 pharmacology Hrs

#### REFERENCES

- 1. Central Drugs Standard Control Organization- Good Clinical Practices, Guidelines for Clinical Trials on Pharmaceutical Products in India. New Delhi: Ministry of Health;2001.
- International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for human use. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice. E6; May 1996. 229
- 3. Ethical Guidelines for Biomedical Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.
- 4. Textbook of Clinical Trials edited by David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.
- 5. Clinical Data Management edited by R K Rondels, S A Varley, C F Webbs. Second Edition, Jan 2000, Wiley Publications.
- 6. Handbook of clinical Research. Julia Lloyd and Ann Raven Ed. Churchill Livingstone.
- 7. Principles of Clinical Research edited by Giovanna di Ignazio, Di Giovanna and Haynes.

#### **Course Outcomes**

The student will try to learn-

- **CO1.** Current necessity in the fields of clinical research and pharmacovigilance.
- CO2. Conceptualising, designing, carrying out, managing, and reporting clinical studies.
- CO3. Pharmacovigilance environment and various safety data generation techniques.
- **CO4.** Developing drug safety data during the pre-clinical, clinical, and post-market surveillance phases of drug development.

**Course Outcomes and their mapping with Programme Outcomes:** 

CO		PO									
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8			
CO1						2					
CO2						2					
CO3							3				
CO4			3								

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

### PHARMACOLOGICAL PRACTICAL – II (MPL 205P)

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MPL 205P	-	-	12	12 hours	50	100	150	6

- 1. To record the DRC of agonist using suitable isolated tissues preparation.
- 2. To study the effects of antagonist/potentiating agents on DRC of agonist using suitable isolated tissue preparation.
- 3. To determine to the strength of unknown sample by matching bioassay by using suitable tissue preparation.
- 4. To determine to the strength of unknown sample by interpolation bioassay by using suitable tissue preparation
- 5. To determine to the strength of unknown sample by bracketing bioassay by using suitable tissue preparation
- 6. To determine to the strength of unknown sample by multiple point bioassay by using suitable tissue preparation.
- 7. Estimation of PA2 values of various antagonists using suitable isolated tissue preparations.
- 8. To study the effects of various drugs on isolated heart preparations
- 9. Recording of rat BP, heart rate and ECG.
- 10. Recording of rat ECG
- 11. Drug absorption studies by averted rat ileum preparation.
- 12. Acute oral toxicity studies as per OECD guidelines.
- 13. Acute dermal toxicity studies as per OECD guidelines.
- 14. Repeated dose toxicity studies- Serum biochemical, haematological, urine analysis, functional observation tests and histological studies.
- 15. Drug mutagenicity study using mice bone-marrow chromosomal aberration test.
- 16. Protocol design for clinical trial. (3 Nos.).
- 17. Design of ADR monitoring protocol.
- 18. In-silico docking studies. (2 Nos.)
- 19. In-silico pharmacophore based screening.
- 20. In-silico QSAR studies.
- 21. ADR reporting

#### REFERENCES

- 1. Fundamentals of experimental Pharmacology-by M.N.Ghosh
- 2. Hand book of Experimental Pharmacology-S.K.Kulakarni
- 3. Text book of in-vitro practical Pharmacology by Ian Kitchen
- 4. Bioassay Techniques for Drug Development by Atta-ur-Rahman, Iqbalchoudhary and William Thomsen
- 5. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
- 6. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists.

#### **Course Outcomes**

The student will try to learn-

**CO1.** To determine to the strength of unknown sample by interpolation, bracketing, bioassay, and multiple point bioassay by using suitable tissue preparation.

CO2. Toxicity studies as per OECD guidelines.

CO3. In-silico QSAR studies.

## **Course Outcomes and their mapping with Programme Outcomes:**

CO		PO							
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	
CO1			2					2	
CO <sub>2</sub>						3			
CO <sub>3</sub>							3		

Weightage: 1-Sightly; 2-Moderately; 3-Strongly

# **Third Semester**

#### **RESEARCH METHODOLOGY & BIOSTATISTICS (MRM 301T)**

Sub Code	L	T	P	Duration	IA	ESE	Total	Credits
MRM 301T	4	-	-	4 hours	25	75	100	4

#### UNIT – I

General Research Methodology: Research, objective, requirements, practical difficulties, review of literature, study design, types of studies, strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.

#### UNIT – II

Biostatistics: Definition, application, sample size, importance of sample size, factors influencing sample size, dropouts, statistical tests of significance, typeof significance tests, parametric tests(students "t" test, ANOVA, Correlationcoefficient, regression), non-parametric tests (wilcoxan rank tests, analysis ofvariance, correlation, chi square test), null hypothesis, P values, degree offreedom, interpretation of P values.

#### UNIT – III

Medical Research: History, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy andbeneficence/non-maleficence, euthanasia, informed consent, confidentiality, criticisms of orthodox medical ethics, importance of communication, controlresolution, guidelines, ethics committees, cultural concerns, truth telling, online business practices, conflicts of interest, referral, vendor relationships, treatment of family members, sexual relationships, fatality.

#### UNIT - IV

CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine, surveillance, diagnosis, treatment and control of disease, personalhygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and training, transport of lab animals.

Declaration of Helsinki: History, introduction, basic principles for all medicalresearch, and additional principles for medical research combined withmedical care.

# **Course Outcomes**

The student will try to learn-

**CO1.** General research methodology, review of literature, biostatics.

CO2. Values of medical ethics.

CO3. CPCSEA guidelines for laboratory animal facility.

# **Course Outcomes and their mapping with Programme Outcomes:**

CO		PO							
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	
CO1						3			
CO <sub>2</sub>								3	
CO <sub>3</sub>								3	

Weightage: 1-Sightly; 2-Moderately; 3-Strongly